Ocugen has pulled off a financing manoeuvre that slashes its interest burden in half, using a $130 million convertible bond to repay a double-digit loan and fund its gene therapy pipeline through 2028. The biotech closed the private placement on 14 May 2026, issuing 6.75% senior convertible notes due in 2034 — a stark improvement from the 12.5% it had been paying on the Avenue Capital Group loan.
The deal started at $115 million, but the initial buyer exercised the greenshoe option in full, pushing the total to $130 million. After discounts and transaction costs, Ocugen walks away with roughly $112.6 million in net proceeds. Of that, $32.7 million went straight to extinguishing the Avenue credit line, including accrued interest and fees. The remaining cash will bankroll three late-stage programmes and multiple regulatory filings.
Conversion terms shift dilution debate down the road
Bondholders can convert into Ocugen shares at about $2.68 per share — a 45% premium over the 4 May closing price of $1.85. That conversion is locked until at least 15 May 2027, or the date Ocugen reserves the maximum required shares, whichever comes first. For now, the share price at around €1.25 ($1.35) keeps any economic conversion distant. The company can redeem the notes from 15 May 2029, provided certain stock price conditions are met, while investors have the right to demand repayment at par plus accrued interest on 15 May 2032.
The dilution risk is real but deferred. With the 6.75% coupon paid semi-annually and a five-year window before any forced conversion, management has bought time to advance its pipeline and, ideally, lift the stock above the conversion threshold.
Three BLA submissions targeted by 2028
Chief executive Shankar Musunuri described the transaction as a milestone that reflects the “strong momentum” in Ocugen’s late-stage pipeline. The new runway stretches to 2028, giving the company enough liquidity to prepare three Biologics License Applications.
Should investors sell immediately? Or is it worth buying Ocugen?
The lead candidate OCU400, a gene therapy for retinal diseases, is scheduled for a rolling BLA submission starting in the third quarter of 2026, with completion expected by the second quarter of 2027. Manufacturing qualification batches are due to wrap up by mid-2026. The pivotal Phase 3 trial liMeliGhT has already enrolled 140 patients.
For OCU410, which targets geographic atrophy, a Phase 3 registration study begins in the third quarter of 2026, and the company aims to file a BLA in 2028. That timeline depends on successful data, but the financing now provides a clear path to execute.
Technicals signal deep oversold territory
The stock has taken a beating in recent weeks, losing roughly 22% over the past month even as it remains solidly positive over twelve months. The relative strength index sits at 25, well into oversold territory, while the 30-day annualised volatility hovers near 90%. That combination of fear and technical exhaustion gives the shares a coiled look, but the catalyst will have to come from clinical execution.
The next chance to reset the narrative comes on 26 May 2026, when Ocugen presents at the Stifel Virtual Ophthalmology Forum. Management will need to connect the new financial flexibility directly to upcoming pipeline milestones if it wants to convince the market that the recent selloff was overdone.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from May 15 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 15.
Ocugen: Buy or sell? Read more here...
